Literature DB >> 17562242

Severe paraneoplastic hyponatremia and hypoosmolality in a patient with small-cell lung carcinoma: syndrome of inappropriate antidiuretic hormone secretion versus atrial natriuretic peptide or both?

Dan Radulescu1, Delia Bunea, Sorin Pripon, Caius Duncea, Letitia Radulescu.   

Abstract

It is well documented in literature that a majority of small-cell lung cancers are associated with paraneoplastic phenomena. We report the case of a 63-year-old man diagnosed with small-cell lung carcinoma, in whom a severe hyponatremia and renal sodium loss with inappropriate antidiuresis were also found during a routine laboratory testing. Syndrome of inappropriate antidiuretic hormone secretion was first suspected in this patient, but another complex pathogenetic mechanism involving atrial natriuretic peptides could be associated, potentiating the deflation of the plasma sodium level. In our patient, the plasma-atrial natriuretic peptide base level, determined with a sensitive radioimmunoassay, was above the normal range (183 pg/mL; normal range, 50 pg/mL, +/- 10 pg/mL), and the antidiuretic hormone plasma level had an oscillatory pattern, varying between 5.5 pg/mL and 7 pg/mL (normal range, 0-4.7 pg/mL). We discuss the pathogenesis and clinical aspects of this association and the therapeutic options for these types of patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17562242     DOI: 10.3816/CLC.2007.n.022

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  2 in total

Review 1.  Paraneoplastic syndromes associated with lung cancer.

Authors:  Nobuhiro Kanaji; Naoki Watanabe; Nobuyuki Kita; Shuji Bandoh; Akira Tadokoro; Tomoya Ishii; Hiroaki Dobashi; Takuya Matsunaga
Journal:  World J Clin Oncol       Date:  2014-08-10

2.  Resolution of severe hyponatraemia is associated with improved survival in patients with cancer.

Authors:  Kirsty Balachandran; Alicia Okines; Ranga Gunapala; Daniel Morganstein; Sanjay Popat
Journal:  BMC Cancer       Date:  2015-03-22       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.